{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:02:52Z","timestamp":1792069372093,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1U01CA243078-01A1"],"award-info":[{"award-number":["1U01CA243078-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1U01CA243078-01A1"],"award-info":[{"award-number":["1U01CA243078-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ethos Discovery"},{"DOI":"10.13039\/100007450","name":"Science Foundation Arizona","doi-asserted-by":"publisher","award":["BSP-0542-13"],"award-info":[{"award-number":["BSP-0542-13"]}],"id":[{"id":"10.13039\/100007450","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Comparative studies of naturally\u00a0occurring canine cancers have provided new insight into many areas of cancer research. Development and validation of circulating tumor DNA (ctDNA) analysis in pet dogs can help address diagnostic needs in veterinary as well as human oncology. Dogs have high incidence of naturally\u00a0occurring spontaneous cancers, demonstrate molecular heterogeneity and clonal evolution during therapy, allow serial sampling of blood from the same individuals during the course of disease progression, and have relatively compressed intervals for disease progression amenable to longitudinal studies. Here, we present a feasibility study of ctDNA analysis performed in 48 dogs including healthy dogs and dogs with either benign splenic lesions or malignant splenic tumors (hemangiosarcoma) using shallow whole genome sequencing (sWGS) of cell-free DNA. To enable detection and quantification of ctDNA using sWGS, we adapted two informatic approaches and compared their performance for the canine genome. At the time of initial clinical presentation, mean ctDNA fraction in dogs with malignant splenic tumors was 11.2%, significantly higher than dogs with benign lesions (3.2%;\n                    <jats:italic>p<\/jats:italic>\n                    =\u00a00.001). ctDNA fraction was 14.3% and 9.0% in dogs with metastatic and localized disease, respectively (\n                    <jats:italic>p<\/jats:italic>\n                    =\u00a00.227). In dogs treated with surgical resection of malignant tumors, mean ctDNA fraction decreased from 11.0% prior to resection to 7.9% post-resection (\n                    <jats:italic>p<\/jats:italic>\n                    =\u00a00.047 for comparison of paired samples). Our results demonstrate that ctDNA analysis is feasible in dogs with hemangiosarcoma using a cost-effective approach such as sWGS. Additional studies are needed to validate these findings, and determine the role of ctDNA to assess burden of disease and treatment response in dogs with cancer.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-09716-6","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T14:03:48Z","timestamp":1650031428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Feasibility of circulating tumor DNA analysis in dogs with naturally occurring malignant and benign splenic lesions"],"prefix":"10.1038","volume":"12","author":[{"given":"Patricia Filippsen","family":"Favaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel D.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradon R.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Cawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Contente-Cuomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukmei","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P. D.","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Trent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chand","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Murtaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"9716_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090028","volume":"9","author":"M Paoloni","year":"2014","unstructured":"Paoloni, M. et al. Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials. PLoS ONE 9, e90028. https:\/\/doi.org\/10.1371\/journal.pone.0090028 (2014).","journal-title":"PLoS ONE"},{"key":"9716_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pharmthera.2018.01.012","volume":"188","author":"DL Gustafson","year":"2018","unstructured":"Gustafson, D. L., Duval, D. L., Regan, D. P. & Thamm, D. H. Canine sarcomas as a surrogate for the human disease. Pharmacol. Ther. 188, 80\u201396. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.01.012 (2018).","journal-title":"Pharmacol. Ther."},{"key":"9716_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrc2273","volume":"8","author":"M Paoloni","year":"2008","unstructured":"Paoloni, M. & Khanna, C. Translation of new cancer treatments from pet dogs to humans. Nat. Rev. Cancer 8, 147\u2013156. https:\/\/doi.org\/10.1038\/nrc2273 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"9716_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tvjl.2016.03.009","volume":"213","author":"LY Pang","year":"2016","unstructured":"Pang, L. Y. & Argyle, D. J. Veterinary oncology: Biology, big data and precision medicine. Vet. J. 213, 38\u201345. https:\/\/doi.org\/10.1016\/j.tvjl.2016.03.009 (2016).","journal-title":"Vet. J."},{"key":"9716_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41568-020-0297-3","volume":"20","author":"AK LeBlanc","year":"2020","unstructured":"LeBlanc, A. K. & Mazcko, C. N. Improving human cancer therapy through the evaluation of pet dogs. Nat. Rev. Cancer 20, 727\u2013742. https:\/\/doi.org\/10.1038\/s41568-020-0297-3 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"9716_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188667","volume":"12","author":"G Wang","year":"2017","unstructured":"Wang, G. et al. Actionable mutations in canine hemangiosarcoma. PLoS ONE 12, e0188667. https:\/\/doi.org\/10.1371\/journal.pone.0188667 (2017).","journal-title":"PLoS ONE"},{"key":"9716_CR7","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1158\/1078-0432.CCR-19-1145","volume":"25","author":"G Lorch","year":"2019","unstructured":"Lorch, G. et al. Identification of recurrent activating HER2 mutations in primary canine pulmonary adenocarcinoma. Clin. Cancer Res. 25, 5866\u20135877. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1145 (2019).","journal-title":"Clin. Cancer Res."},{"key":"9716_CR8","doi-asserted-by":"publisher","unstructured":"Wong, S. et al. Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients. bioRxiv, 2020.2011.2015.380048. https:\/\/doi.org\/10.1101\/2020.11.15.380048 (2020).","DOI":"10.1101\/2020.11.15.380048"},{"key":"9716_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2021.664718","volume":"8","author":"J Chibuk","year":"2021","unstructured":"Chibuk, J. et al. Horizons in Veterinary precision oncology: Fundamentals of cancer genomics and applications of liquid biopsy for the detection, characterization, and management of cancer in dogs. Front Vet. Sci. 8, 664718. https:\/\/doi.org\/10.3389\/fvets.2021.664718 (2021).","journal-title":"Front Vet. Sci."},{"key":"9716_CR10","doi-asserted-by":"publisher","unstructured":"Budhraja, K. K. et al. Analysis of fragment ends in plasma DNA from patients with cancer. medRxiv, 2021.2004.2023.21255935. https:\/\/doi.org\/10.1101\/2021.04.23.21255935 (2021).","DOI":"10.1101\/2021.04.23.21255935"},{"key":"9716_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.pharmthera.2017.02.003","volume":"174","author":"N Perdigones","year":"2017","unstructured":"Perdigones, N. & Murtaza, M. Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis. Pharmacol. Ther. 174, 22\u201326. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.003 (2017).","journal-title":"Pharmacol. Ther."},{"key":"9716_CR12","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","volume":"368","author":"SJ Dawson","year":"2013","unstructured":"Dawson, S. J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. New Engl. J. Med. 368, 1199\u20131209. https:\/\/doi.org\/10.1056\/NEJMoa1213261 (2013).","journal-title":"New Engl. J. Med."},{"key":"9716_CR13","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201707945","author":"DWY Tsui","year":"2018","unstructured":"Tsui, D. W. Y. et al. Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer. EMBO Mol. Med. https:\/\/doi.org\/10.15252\/emmm.201707945 (2018).","journal-title":"EMBO Mol. Med."},{"key":"9716_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax7392","author":"BR McDonald","year":"2019","unstructured":"McDonald, B. R. et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aax7392 (2019).","journal-title":"Sci. Transl. Med."},{"key":"9716_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232365","volume":"15","author":"M Tagawa","year":"2020","unstructured":"Tagawa, M. et al. Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma. PLoS ONE 15, e0232365. https:\/\/doi.org\/10.1371\/journal.pone.0232365 (2020).","journal-title":"PLoS ONE"},{"key":"9716_CR16","doi-asserted-by":"publisher","first-page":"e0169454","DOI":"10.1371\/journal.pone.0169454","volume":"12","author":"G Beffagna","year":"2017","unstructured":"Beffagna, G. et al. Circulating cell-free DNA in dogs with mammary tumors: Short and long fragments and integrity index. PLoS ONE 12, e0169454 (2017).","journal-title":"PLoS ONE"},{"key":"9716_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1476-5829.2007.00122.x","volume":"5","author":"DM Schaefer","year":"2007","unstructured":"Schaefer, D. M. et al. Quantification of plasma DNA as a prognostic indicator in canine lymphoid neoplasia. Vet. Comp. Oncol. 5, 145\u2013155. https:\/\/doi.org\/10.1111\/j.1476-5829.2007.00122.x (2007).","journal-title":"Vet. Comp. Oncol."},{"key":"9716_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075485","volume":"8","author":"J Beck","year":"2013","unstructured":"Beck, J. et al. Genome aberrations in canine mammary carcinomas and their detection in cell-free plasma DNA. PLoS ONE 8, e75485. https:\/\/doi.org\/10.1371\/journal.pone.0075485 (2013).","journal-title":"PLoS ONE"},{"key":"9716_CR19","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-19-0221","author":"K Megquier","year":"2019","unstructured":"Megquier, K. et al. Comparative genomics reveals shared mutational landscape in canine hemangiosarcoma and human angiosarcoma. Mol. Cancer Res. https:\/\/doi.org\/10.1158\/1541-7786.mcr-19-0221 (2019).","journal-title":"Mol. Cancer Res."},{"key":"9716_CR20","unstructured":"Jiang, P. et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. PNAS, E1317-E1325 (2015)."},{"key":"9716_CR21","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ng.3686","volume":"48","author":"M Murtaza","year":"2016","unstructured":"Murtaza, M. & Caldas, C. Nucleosome mapping in plasma DNA predicts cancer gene expression. Nat. Genet. 48, 1105\u20131106 (2016).","journal-title":"Nat. Genet."},{"key":"9716_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz3088","author":"H Markus","year":"2021","unstructured":"Markus, H. et al. Analysis of recurrently protected genomic regions in cell-free DNA found in urine. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaz3088 (2021).","journal-title":"Sci. Transl. Med."},{"key":"9716_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12621","author":"SD Stewart","year":"2020","unstructured":"Stewart, S. D., Ehrhart, E. J., Davies, R. & Khanna, C. Prospective observational study of dogs with splenic mass rupture suggests potentially lower risk of malignancy and more favourable perioperative outcomes. Vet. Comp. Oncol. https:\/\/doi.org\/10.1111\/vco.12621 (2020).","journal-title":"Vet. Comp. Oncol."},{"key":"9716_CR24","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson, V. A. et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat. Commun. 8, 1324. https:\/\/doi.org\/10.1038\/s41467-017-00965-y (2017).","journal-title":"Nat. Commun."},{"key":"9716_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gm439","volume":"5","author":"C Farris","year":"2013","unstructured":"Farris, C. & Trimarchi, J. M. Plasma-seq: A novel strategy for metastatic prostate cancer analysis. Genome Med. 5, 1\u20133 (2013).","journal-title":"Genome Med."},{"key":"9716_CR26","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41. https:\/\/doi.org\/10.1186\/gb-2011-12-4-r41 (2011).","journal-title":"Genome Biol."},{"key":"9716_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","volume":"164","author":"MW Snyder","year":"2016","unstructured":"Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M. & Shendure, J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164, 57\u201368. https:\/\/doi.org\/10.1016\/j.cell.2015.11.050 (2016).","journal-title":"Cell"},{"key":"9716_CR28","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: An ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"key":"9716_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091172","volume":"9","author":"MP Hoeppner","year":"2014","unstructured":"Hoeppner, M. P. et al. An improved canine genome and a comprehensive catalogue of coding genes and non-coding transcripts. PLoS ONE 9, e91172. https:\/\/doi.org\/10.1371\/journal.pone.0091172 (2014).","journal-title":"PLoS ONE"},{"key":"9716_CR30","doi-asserted-by":"publisher","unstructured":"Pockrandt, C., Alzamel, M., Iliopoulos, C. S. & Reinert, K. GenMap: Fast and Exact Computation of Genome Mappability. bioRxiv. https:\/\/doi.org\/10.1101\/611160 (2019).","DOI":"10.1101\/611160"},{"key":"9716_CR31","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan, A. R. & Hall, I. M. BEDTools: A flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841\u2013842 (2010).","journal-title":"Bioinformatics"},{"key":"9716_CR32","unstructured":"HMMcopy: Copy number prediction with correction for GC and mappability bias for HTS data. R package version 1.30.0. (http:\/\/www.bioconductor.org, 2020)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09716-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09716-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09716-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T21:07:24Z","timestamp":1669324044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09716-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9716"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-09716-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]},"assertion":[{"value":"1 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SDS, JC and CK are current or former employees of Ethos Veterinary Health. MM serves on the scientific advisory board of PetDx. WH is a current employee of Vidium Animal Health. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6337"}}